{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:40:20Z","timestamp":1791193220214,"version":"4.1.0"},"reference-count":37,"publisher":"Wiley","issue":"14","license":[{"start":{"date-parts":[[2011,6,24]],"date-time":"2011-06-24T00:00:00Z","timestamp":1308873600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Electrophoresis"],"published-print":{"date-parts":[[2011,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Imatinib (IMAT) is a tyrosine kinase inhibitor that has been used for the treatment of chronic myeloid leukemia (CML). Despite the efficacy of IMAT therapy, some cases of treatment resistance have been described in CML. Developing a plasma method is important since there are several studies that provided a higher correlation between IMAT plasma concentration and response to treatment. Therefore, in this investigation we validated a method by CE as an alternative, new, simple and fast electrophoretic method for IMAT determination in human plasma. The analysis was performed using a fused silica capillary (50\u2009\u03bcm id\u00d746.5\u2009cm total length, 38.0\u2009cm effective length); 50\u2009mmol\/L sodium phosphate buffer, pH 2.5, as BGE; hydrodynamic injection time of 20\u2009s (50\u2009mbar); voltage of 30\u2009kV; capillary temperature of 35\u00b0C and detection at 200\u2009nm. Plasma samples pre\u2010treatment involved liquid\u2013liquid extraction with methyl\u2010<jats:italic>tert<\/jats:italic>\u2010butyl ether as the extracting solvent. The method was linear from 0.125 to 5.00\u2009\u03bcg\/mL. The LOQ was 0.125\u2009\u03bcg\/mL. Mean absolute recovery of IMAT was 67%. The method showed to be precise and accurate with RSD and relative error values lower than 15%. Furthermore, the application of the method was performed in the analysis of plasma samples from CML patients undergoing treatment with IMAT.<\/jats:p>","DOI":"10.1002\/elps.201000642","type":"journal-article","created":{"date-parts":[[2011,6,30]],"date-time":"2011-06-30T06:25:39Z","timestamp":1309415139000},"page":"1885-1892","source":"Crossref","is-referenced-by-count":25,"title":["Capillary electrophoresis method for plasmatic determination of imatinib mesylate in chronic myeloid leukemia patients"],"prefix":"10.1002","volume":"32","author":[{"given":"Tatiana O.","family":"Ajimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyller B.","family":"Borges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline F.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fab\u00edola A.","family":"de Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiane M.","family":"de Gaitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,6,24]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"880","volume-title":"The Merck Index. An Encyclopedia of Chemicals, Drugs and Biologicals","author":"O'Neil M. J.","year":"2001"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/243290a0"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2408149"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441401"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70342-X"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1124\/pr.55.3.4"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036012"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.03.050"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116475"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2009.09.007"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0731-7085(03)00419-9"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2003.10.018"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2003.12.029"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/10826070500330976"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2006.07.022"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2006.12.033"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2004.01.006"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2004.01.032"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2003.10.025"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.816"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2006.08.004"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2009.08.005"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2009.10.007"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2009.11.009"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0731-7085(02)00080-8"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1570-0232(01)00611-0"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1570-0232(03)00206-X"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9673(03)00775-1"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ftd.0000175973.71140.91"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2179"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2009.04.028"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2009.04.045"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1570-0232(03)00518-X"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2004.09.089"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0731-7085(99)00088-6"},{"key":"e_1_2_6_37_2","unstructured":"International Conference on Harmonization (ICH) Validation of Analytical Procedures: Methodology Technical Requirements for the Registration of Pharmaceuticals for Human Use Geneva Switzerland 1996."},{"key":"e_1_2_6_38_2","unstructured":"The United States Pharmacopeia 30th Revision. The United States Pharmacopeial Convention Validation of Compendial Procedures Chap. 1225 Rockville 2007 pp. 680\u2013683."}],"container-title":["ELECTROPHORESIS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Felps.201000642","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/elps.201000642","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T09:56:25Z","timestamp":1760522185000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/elps.201000642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,24]]},"references-count":37,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["10.1002\/elps.201000642"],"URL":"https:\/\/doi.org\/10.1002\/elps.201000642","archive":["Portico"],"relation":{},"ISSN":["0173-0835","1522-2683"],"issn-type":[{"value":"0173-0835","type":"print"},{"value":"1522-2683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,24]]}}}